GLP-1 Lawsuits: What the Claims Allege, and What the Evidence Actually Shows

Attorney ads about GLP-1 lawsuits are hard to avoid, and they tend to blur two things that are actually quite different: what's legally alleged in an active case, and what peer-reviewed evidence has actually found. Both matter, but they're not the same question, and a site built on "checked and updated" evidence owes you the distinction. Here's what's real, sourced to the federal court's own docket and to the underlying medical literature — not to a law firm's marketing page.

The two active federal litigations

The U.S. Judicial Panel on Multidistrict Litigation (JPML) — the federal body that consolidates related lawsuits filed across the country into a single court for pretrial proceedings — currently lists two active, separate GLP-1 litigations, both centralized before the same judge in the Eastern District of Pennsylvania¹. MDL 3094, "IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation," was formed in February 2024 and covers the broader set of injury claims, primarily gastrointestinal¹. A second, separate litigation — MDL 3163, "IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation" — was formed in December 2025 specifically to consolidate vision-loss claims, reflecting that NAION claims had grown numerous enough to warrant their own separate docket rather than staying folded into the general case¹. Both are civil products-liability litigation: allegations that the manufacturers failed to adequately warn about risks, not criminal proceedings, and consolidation for pretrial purposes is not a court ruling that the allegations are true — it's a case-management step that happens whenever enough similar lawsuits are filed nationwide.

What the gastrointestinal claims are built on

The gastroparesis and related GI claims didn't emerge from nowhere — they trace substantially to a 2023 JAMA study that used a large U.S. health claims database (PharMetrics Plus, covering roughly 93% of outpatient prescriptions and diagnoses nationally) to compare GLP-1 users against a bupropion-naltrexone comparator group². Among 613 semaglutide users and 4,144 liraglutide users versus 654 people on bupropion-naltrexone, the adjusted hazard ratio for gastroparesis was 3.67 (95% CI, 1.15-11.90) and for pancreatitis was 9.09 (95% CI, 1.25-66.00); biliary disease was elevated but not statistically significant (HR 1.50, 95% CI 0.89-2.53)². Read those confidence intervals carefully — they're wide, a direct consequence of how few gastroparesis and pancreatitis events occurred in a study this size, and the authors themselves noted a real limitation: "although all GLP-1 agonist users had a record for obesity without diabetes, whether GLP-1 agonists were all used for weight loss is uncertain"². Wide confidence intervals and an uncertain-indication caveat don't mean the finding is wrong — they mean it's a real signal from a study built to detect one, not proof of the exact magnitude of individual risk.

What the vision-loss claims are built on

We cover the original 2024 NAION (nonarteritic anterior ischemic optic neuropathy, a cause of sudden vision loss) signal in full in GLP-1 boxed warnings: what the label actually says. The evidence base has grown since then: a large Danish cohort study following 424,152 people with type 2 diabetes over five years (2018-2024) — 106,454 exposed to semaglutide, 317,698 not — found a hazard ratio of 2.19 (95% CI, 1.54-3.12) for NAION, with 67 of 218 total cases occurring in semaglutide users, and a median time to onset of about 22 months after starting the drug³. The study's authors were direct about what this means: "use of once-weekly semaglutide independently more than doubled the risk of NAION. Given the irreversible nature of NAION, it is important to acknowledge this risk"³ — while also noting NAION remains "an untreatable condition often causing severe and irreversible visual loss" regardless of cause, and that identifying who's at elevated risk is still an open research question.

Association is not the same as a proven mechanism — and that's exactly why it's worth knowing

Every study behind both litigations is observational — comparing outcomes in people who happened to be prescribed a GLP-1 against people who weren't, not a randomized trial designed to isolate causation. That's a real limitation, and it cuts both ways: it means these findings can be confounded by factors that led a physician to prescribe (or not prescribe) a GLP-1 in the first place, but it also means the signal isn't something a trial sponsor's own randomized data was designed to catch, since none of the pivotal weight-loss trials were statistically powered to detect rare events like gastroparesis or NAION in the first place. That's precisely the gap a lawsuit's discovery process and a plaintiff's expert testimony are built to probe — and precisely why "not yet proven causal in a randomized trial" and "not a real risk worth knowing about before you start" are two very different statements. The rare pancreatitis and gastrointestinal risks are also acknowledged directly in current FDA labeling as a class-wide warning, separate from and prior to the litigation itself⁴.

What this means for you, practically

None of this is a reason to panic, and it's not legal advice — if you believe you were injured, that's a conversation for an attorney, not a savings site. What it is a reason for: disclosing your full history to a prescriber before starting, including any personal history of gastroparesis, pancreatitis, or eye conditions like NAION risk factors (certain optic nerve anatomy, uncontrolled diabetes, some cardiovascular risk factors), the same disclosure principle covered in GLP-1 drug interactions: what to tell your prescriber. A program with a thin, rushed intake that never asks about these histories is skipping exactly the questions this evidence says matter.

Where this fits your provider decision

If a program's marketing leans entirely on speed and price with no real medical intake, that's worth weighing against what this evidence shows about the value of a prescriber who actually asks about your history before writing a prescription — a concern that applies even more directly to unverified compounding sources, covered in how to verify a compounding pharmacy is legitimate. See how we score real medical oversight in our Value Score methodology.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.